These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6167802)

  • 1. Haemodynamic dose-response effects of intravenous oxprenolol in coronary heart disease.
    Silke B; Hilal A; Taylor SH
    J Cardiovasc Pharmacol; 1981; 3(4):716-27. PubMed ID: 6167802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic dose-response effects of intravenous beta-blocking drugs with different ancillary properties in patients with coronary heart disease.
    Taylor SH; Silke B; Lee PS; Hilal A
    Eur Heart J; 1982 Dec; 3(6):564-9. PubMed ID: 6130944
    [No Abstract]   [Full Text] [Related]  

  • 3. Haemodynamic dose-response effects of i.v. metoprolol in coronary heart disease.
    Hendry WG; Silke B; Taylor SH
    Eur J Clin Pharmacol; 1981; 19(5):323-7. PubMed ID: 7238560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative haemodynamic dose-response effects of intravenous propranolol and pindolol in patients with coronary heart disease.
    Silke B; Nelson GI; Ahuja RC; Okoli RC; Taylor SH
    Eur J Clin Pharmacol; 1983; 25(2):157-65. PubMed ID: 6628498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of oxprenolol alone and combined with nitroglycerin in patients with ischemic heart disease.
    Lecerof H; Malmborg RO
    Acta Med Scand; 1972 Dec; 192(6):499-506. PubMed ID: 4629694
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease.
    Silke B; Nelson GI; Ahuja RC; Taylor SH
    Br Heart J; 1982 Oct; 48(4):364-71. PubMed ID: 7126388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodynamic dose-response effects of i.v. nicardipine in coronary artery disease.
    Silke B; Verma SP; Nelson GI; Hussain M; Taylor SH
    Br J Clin Pharmacol; 1984 Nov; 18(5):717-24. PubMed ID: 6508981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oxprenolol in normal subjects.
    Mason WD; Winer N
    Clin Pharmacol Ther; 1976 Oct; 20(4):401-12. PubMed ID: 10124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A haemodynamic and radionuclide assessment of diltiazem in coronary heart disease.
    Silke B; Sharma SK; Verma SP; Midtbo KA; Reynolds G; Taylor SH
    Br J Clin Pharmacol; 1987 Feb; 23(2):165-72. PubMed ID: 3828193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combination of beta-receptor blocking and vasodilator agent.
    Koch G
    Br Heart J; 1976 Dec; 38(12):1240-6. PubMed ID: 1008968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodynamic effects of bisoprolol in patients with coronary heart disease: influence of various bisoprolol plasma concentrations.
    Bonelli J; Staribacher H
    J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S83-6. PubMed ID: 2439805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of oxprenolol dosage time on its pharmacokinetics and haemodynamic effects during exercise in man.
    Koopmans R; Oosterhuis B; Karemaker JM; Wemer J; van Boxtel CJ
    Eur J Clin Pharmacol; 1993; 44(2):171-6. PubMed ID: 8453962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?
    Taylor SH; Silke B; Lee PS
    N Engl J Med; 1982 Mar; 306(11):631-5. PubMed ID: 6120457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-blockade reverses regional dysfunction in ischemic myocardium.
    Leone BJ; Lehot JJ; Francis CM; Cutfield GR; Foëx P
    Anesth Analg; 1987 Jul; 66(7):607-14. PubMed ID: 2886076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic dose-response effects of intravenous nisoldipine in coronary artery disease.
    Silke B; Frais MA; Muller P; Verma SP; Reynolds G; Taylor SH
    Br J Clin Pharmacol; 1985 Dec; 20(6):675-80. PubMed ID: 4091998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.
    Brunner L; Imhof P; Jack D
    Eur J Clin Pharmacol; 1975; 8(1):3-9. PubMed ID: 786674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris.
    Silke B; Verma SP; Hussain M; Nelson GI; Okoli RC; Taylor SH
    Br J Clin Pharmacol; 1983 Nov; 16(5):529-35. PubMed ID: 6315039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation and maintenance of beta-blockade with intravenous oxprenolol.
    Silke B; John VA; Calvert RT; Taylor SH
    Eur J Clin Pharmacol; 1983; 24(1):7-14. PubMed ID: 6832204
    [No Abstract]   [Full Text] [Related]  

  • 19. Beta-blockade in ischaemic heart disease--influence of concomitant ISA or alpha-blockade on haemodynamic profile.
    Silke B; Nelson GI; Ahuja RC; Taylor SH
    Postgrad Med J; 1983; 59 Suppl 3():45-52. PubMed ID: 6359109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic dose-response effects of i.v. verapamil in coronary artery disease.
    Silke B; Verma SP; Ahuja RC; Nelson GI; Hussain M; Taylor SH
    Herz; 1984 Dec; 9(6):353-61. PubMed ID: 6510876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.